SC
PLX icon

Savant Capital’s Protalix BioTherapeutics PLX Stock Holding History

Savant Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,996
Closed -$14K – 1449
2024
Q2 		$14K Buy
+11,996
New +$14.2K ﹤0.01% 1255

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Savant Capital's PLX Position: Q3 2024 in Review

Savant Capital sold out of Protalix BioTherapeutics (PLX) in Q3 2024, closing a stake of 11,996 shares — an estimated $14K sold.

Savant Capital first reported a position in PLX in Q2 2024 and held it in 1 quarter. The position peaked at $14K in Q2 2024. 45 funds tracked by Wall St. Rank hold PLX as of Q3 2024.

  • Savant Capital reported no remaining Protalix BioTherapeutics position as of Q3 2024 after selling out during the quarter.
  • Savant Capital sold 11,996 Protalix BioTherapeutics shares in Q3 2024, an estimated $14K.
  • Savant Capital first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 1 quarter.
  • Savant Capital's Protalix BioTherapeutics position peaked at $14K in Q2 2024.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2024.

Based on Savant Capital's 13F filing for Q3 2024, filed 4 Nov 2024.